Oncology & Cancer

SABCS: Extending tamoxifen to 10 years beneficial in breast CA

(HealthDay)—For women with estrogen receptor (ER)-positive early breast cancer, continuing tamoxifen to 10 years correlates with reduced risk of recurrence and lower breast cancer-specific and overall mortality, according ...

page 12 from 21